PDF下载 ( 302 KB)
Guideline for diagnosis and treatment of liver failure(2018)
-
摘要:
<正>肝衰竭是临床常见的严重肝病症候群,病死率极高。多年来,各国学者对肝衰竭的定义、病因、分类、分型、诊断和治疗、预后判断等问题不断进行探索。2005年,美国肝病学会(AASLD)发布了《急性肝衰竭处理》[1]的建议书。2006年10月,中华医学会感染病学分会肝衰竭与人工肝学组和中华医学会肝病学分会重型肝病与人工肝学组制订了我国第一部《肝衰竭诊疗指南》[2],从定义、诱因、分类、诊断和治疗等方面对肝衰竭进行了系统而精要的阐述,既与国际接轨,又独具中国特色,
-
Key words:
- liver failure /
- artificial liver /
- diagnosis /
- treatment /
- guideline
-
[1]POLSON J, LEE WM.AASLD position paper:The management of acute liver failure[J].Hepatology, 2005, 41 (5) :1179-1197. [2]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure[J].Inter J Epidemiol Infect Dis, 2006, 33 (4) :217-221. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].国际流行病学传染病学杂志, 2006, 33 (4) :217-221. [3] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, CMA;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, CMA.Guideline for diagnosis and treatment of liver failure[J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327. [4]SARIN SK, KEDARISETTY CK, ABBAS Z, et al.Acute-onchronic liver failure:Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471. [5]European Association for the Study of the Liver.EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J].J Hepatol, 2017, 66 (5) :1047-1081. [6]FLAMM SL, YANG YX, SINGH S, et al.American gastroenterological association institute guidelines for the diagnosis and management of acute liver failure[J].Gastroenterology, 2017, 152 (3) :644-647. [7]WU T, LI J, SHAO L, et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-onchronic liver failure[J].Gut, 2018, 67 (12) :2181-2191. [8]JALAN R, YURDAYDIN C, BAJAJ JS, et al.Toward an improved definition of acute-on-chronic liver failure[J].Gastroenterology, 2014, 147 (1) :4-10. [9]ZHANG Q, LI Y, HAN T, et al.Comparison of current diagnostic criteria for acute-on-chronic liver failure[J/OL].PLo S One, 2015, 10 (3) :e0122158. [10]European Association for the Study of the Liver.EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J].JHepatol, 2019, 70 (1) :172-193. [11]CHEN Y, YANG F, LU H, et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology, 2011, 54 (2) :562-572. [12]TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044. [13]PETROF EO, KHORUTS A.From stool transplants to nextgeneration microbiota therapeutics[J].Gastroenterology, 2014, 146 (6) :1573-1582. [14]ROCKEY DC, SEEFF LB, ROCHON J, et al.Causality assessment in drug-induced liver injury using a structured expert opinion process:Comparison to the Roussel-Uclaf causality assessment method[J].Hepatology, 2010, 51 (6) :2117-2126. [15]JINDAL A, KUMAR M, SARIN SK.Management of acute hepatitis B and reactivation of hepatitis B[J].Liver Int, 2013, 33 (Suppl 1) :164-175. [16]SUN LJ, YU JW, ZHAO YH, et al.Influential factors of prognosis in lamivudine treatment for patients with acute-onchronic hepatitis B liver failure[J].J Gastroenterol Hepatol, 2010, 25 (3) :583-590. [17]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol, 2018, 69 (2) :461-511. [18]SMILKSTEIN MJ, KNAPP GL, KULIG KW, et al.Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose.Analysis of the national multicenter study (1976 to1985) [J].N Engl J Med, 1988, 319 (24) :1557-1562. [19]KEAYS R, HARRISON PM, WENDON JA, et al.Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure:A prospective controlled trial[J].BMJ, 1991, 303 (6809) :1026-1029. [20]LEE WM, HYNAN LS, ROSSARO L, et al.Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure[J].Gastroenterology, 2009, 137 (3) :856-864. [21]HRUBY K, CSOMOS G, FUHRMANN M, et al.Chemotherapy of amanita phalloides poisoning with intravenous silibinin[J].Hum Toxicol, 1983, 2 (2) :183-195. [22]BROUSSARD CN, AGGARWAL A, LACEY SR, et al.Mushroom poisoning-from diarrhea to liver transplantation[J].Am J Gastroenterol, 2001, 96 (11) :3195-3198. [23]ENJALBERT F, RAPIOR S, NOUGUIER-SOULJ, et al.Treatment of amatoxin poisoning:20-year retrospective analysis[J].J Toxicol Clin Toxicol, 2002, 40 (6) :715-757. [24]CANALESE J, GIMSON AE, DAVIS C, et al.Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure[J].Gut, 1982, 23 (7) :625-629. [25]KLINCK J, MCNEILL L, di ANGELANTONIO E, et al.Predictors and outcome impact of perioperative serum sodium changes in a high-risk population[J].Br J Anaesth, 2015, 114 (4) :615-622. [26]JALAN R, OLDE DAMINK SW, DEUTZ NE, et al.Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia[J].Hepatology, 2001, 34 (1) :50-54. [27]JALAN R, O DAMINK SW, DEUTZ NE, et al.Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure[J].Lancet, 1999, 354 (9185) :1164-1168. [28]TOFTENG F, LARSEN FS.The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure[J].J Cereb Blood Flow Metab, 2004, 24 (7) :798-804. [29]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J].J Clin Hepatol, 2018, 34 (10) :2076-2089. (in Chinese) 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J].临床肝胆病杂志, 2018, 34 (10) :2076-2089. [30]VILSTRUP H, AMODIO P, BAJAJ J, et al.Hepatic encephalopathy in chronic liver disease:2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J].Hepatology, 2014, 60 (2) :715-735. [31]GLUUD LL, VILSTRUP H, MORGAN MY.Nonabsorbable disaccharides for hepatic encephalopathy:A systematic review and meta-analysis[J].Hepatology, 2016, 64 (3) :908-922. [32]GLUUD LL, VILSTRUP H, MORGAN MY.Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis[J].Cochrane Database Syst Rev, 2016, (5) :CD003044. [33]BAI M, YANG Z, QI X, et al.L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis:A meta-analysis of randomized controlled trials[J].J Gastroenterol Hepatol, 2013, 28 (5) :783-792. [34]GLUUD LL, DAM G, LES I, et al.Branched-chain amino acids for people with hepatic encephalopathy[J].Cochrane Database Syst Rev, 2017, 5:CD001939. [35]LACCETTI M, MANES G, UOMO G, et al.Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients:A double blind randomized placebo controlled study[J].Dig Liver Dis, 2000, 32 (4) :335-338. [36]HANISH SI, STEIN DM, SCALEA JR, et al.Molecular adsorbent recirculating system effectively replaces hepatic function in severe acute liver failure[J].Ann Surg, 2017, 266 (4) :677-684. [37]SALIBA F, CAMUS C, DURAND F, et al.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure:A randomized, controlled trial[J].Ann Intern Med, 2013, 159 (8) :522-531. [38]ROLANDO N, PHILPOTT-HOWARD J, WILLIAMS R.Bacterial and fungal infection in acute liver failure[J].Semin Liver Dis, 1996, 16 (4) :389-402. [39]SILVESTRE JP, COELHO LM, PVOA PM.Impact of fulminant hepatic failure in C-reactive protein?[J].J Crit Care, 2010, 25 (4) :657.e7-e12. [40]RULE JA, HYNAN LS, ATTAR N, et al.Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure[J/OL].PLo S One, 2015, 10 (9) :e0138566. [41]KARVELLAS CJ, CAVAZOS J, BATTENHOUSE H, et al.Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure:A retrospective cohort study[J].Clin Gastroenterol Hepatol, 2014, 12 (11) :1942-1949.e1. [42]BERNAL W, AUZINGER G, DHAWAN A, et al.Acute liver failure[J].Lancet, 2010, 376 (9736) :190-201. [43]FARMAKIOTIS D, KONTOYIANNIS DP.Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients[J].Am J Transplant, 2015, 15 (5) :1141-1147. [44]UOJIMA H, KINBARA T, HIDAKA H, et al.Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites[J].Hepatol Res, 2017, 47 (3) :e14-e21. [45]YAN L, XIE F, LU J, et al.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites:A meta-analysis of randomized controlled trials[J].BMC Gastroenterol, 2015, 15:65. [46]European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460. [47]MINDIKOGLU AL, PAPPAS SC.New developments in hepatorenal syndrome[J].Clin Gastroenterol Hepatol, 2018, 16 (2) :162-177.e1. [48]SELBY NM, KUBBA AK, HAWKEY CJ.Acid suppression in peptic ulcer haemorrhage:A'meta-analysis'[J].Aliment Pharmacol Ther, 2000, 14 (9) :1119-1126. [49]LEONTIADIS GI, SHARMA VK, HOWDEN CW.Proton pump inhibitor therapy for peptic ulcer bleeding:Cochrane collaboration meta-analysis of randomized controlled trials[J].Mayo Clin Proc, 2007, 82 (3) :286-296. [50]IOANNOU G, DOUST J, ROCKEY DC.Terlipressin for acute esophageal variceal hemorrhage[J].Cochrane Database Syst Rev, 2003 (1) :CD002147. [51]IMPERIALE TF, TERAN JC, MCCULLOUGH AJ.A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage[J].Gastroenterology, 1995, 109 (4) :1289-1294. [52]LAINE L, COOK D.Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding.A meta-analysis[J].Ann Intern Med, 1995, 123 (4) :280-287. [53]LIN LL, DU SM, FU Y, et al.Combination therapy versus pharmacotherapy, endoscopic variceal ligation, or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding:A meta-analysis of randomized controlled trials[J].Oncotarget, 2017, 8 (34) :57399-57408. [54]PEREIRA SP, ROWBOTHAM D, FITT S, et al.Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease[J].J Hepatol, 2005, 42 (3) :365-370. [55] Liver Failure and Artificial Liver Group, Branch of Infectious Diseases, Chinese Medical Association.Guideline for non-bioartificial liver support systems in treatment of liver failure:2016 update[J].Chin J Clin Infect Dis, 2016, 9 (2) :97-103. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝治疗肝衰竭指南 (2016年版) [J].中华临床感染病杂志, 2016, 9 (2) :97-103. [56]STEADMAN RH, van RENSBURG A, KRAMER DJ.Transplantation for acute liver failure:Perioperative management[J].Curr Opin Organ Transplant, 2010, 15 (3) :368-373. [57]LING Q, XU X, WEI Q, et al.Downgrading MELD improves the outcomes after liver transplantation in patients with acuteon-chronic hepatitis B liver failure[J/OL].PLo S One, 2012, 7 (1) :e30322. [58]MOCHIDA S.Indication criteria for liver transplantation for acute liver failure in Japan[J].Hepatol Res, 2008, 38 (Suppl1) :s52-s55. [59]RAO HY, GUO F, WEI L.Introduction and comments on AASLDpractice guidelines:Diagnosis and treatment of acute liver failure and assessment of liver transplant patients[J].Chin J Hepatol, 2006, 14 (2) :154-156. (in Chinese) 饶慧瑛, 郭芳, 魏来.2005年美国肝病学会急性肝衰竭诊治和肝移植患者评价指南简介[J].中华肝脏病杂志, 2006, 14 (2) :154-156. [60]ARROYO V, MOREAU R, KAMATH PS, et al.Acute-onchronic liver failure in cirrhosis[J].Nat Rev Dis Primers, 2016, 2:16041. [61]LINECKER M, KRONES T, BERG T, et al.Potentially inappropriate liver transplantation in the era of the"sickest first"policy-A search for the upper limits[J].J Hepatol, 2017.[Epub ahead of print] -
本文二维码
计量
- 文章访问数: 1554
- HTML全文浏览量: 150
- PDF下载量: 2510
- 被引次数: 0
下载:
